Insider Selling: Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) CFO Sells 546 Shares of Stock

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) CFO Timothy Eugene Sullivan sold 546 shares of the firm’s stock in a transaction that occurred on Wednesday, January 29th. The stock was sold at an average price of $29.52, for a total transaction of $16,117.92. Following the sale, the chief financial officer now directly owns 128,665 shares in the company, valued at $3,798,190.80. The trade was a 0.42 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink.

Timothy Eugene Sullivan also recently made the following trade(s):

• On Wednesday, January 22nd, Timothy Eugene Sullivan sold 3,088 shares of Apellis Pharmaceuticals stock. The stock was sold at an average price of $30.43, for a total transaction of $93,967.84.
• On Friday, January 17th, Timothy Eugene Sullivan sold 1,730 shares of Apellis Pharmaceuticals stock. The shares were sold at an average price of $29.96, for a total transaction of $51,830.80.
• On Monday, January 13th, Timothy Eugene Sullivan sold 2,170 shares of Apellis Pharmaceuticals stock. The shares were sold at an average price of $28.70, for a total transaction of $62,279.00.

Apellis Pharmaceuticals Trading Up 3.3 %

NASDAQ APLS traded up $0.99 during trading on Thursday, hitting $30.46. The stock had a trading volume of 232,907 shares, compared to its average volume of 1,954,741. Apellis Pharmaceuticals, Inc. has a twelve month low of $24.34 and a twelve month high of $71.90. The company has a market capitalization of $3.79 billion, a PE ratio of -14.99 and a beta of 0.94. The company has a quick ratio of 3.73, a current ratio of 4.36 and a debt-to-equity ratio of 1.91. The firm has a 50 day moving average price of $32.20 and a 200 day moving average price of $32.96.

Apellis Pharmaceuticals (NASDAQ:APLS) last announced its quarterly earnings results on Tuesday, November 5th. The company reported ($0.46) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.32) by ($0.14). The business had revenue of $196.83 million during the quarter, compared to analyst estimates of $200.00 million. Apellis Pharmaceuticals had a negative net margin of 34.97% and a negative return on equity of 103.11%. The business’s revenue for the quarter was up 78.3% compared to the same quarter last year. During the same period last year, the company earned ($1.17) earnings per share. As a group, equities research analysts forecast that Apellis Pharmaceuticals, Inc. will post -1.7 earnings per share for the current year.

Hedge Funds Weigh In On Apellis Pharmaceuticals

A number of institutional investors and hedge funds have recently added to or reduced their stakes in APLS. Braidwell LP lifted its stake in Apellis Pharmaceuticals by 410.8% in the third quarter. Braidwell LP now owns 3,125,183 shares of the company’s stock valued at $90,130,000 after buying an additional 2,513,383 shares during the last quarter. Assenagon Asset Management S.A. lifted its stake in Apellis Pharmaceuticals by 191.9% in the third quarter. Assenagon Asset Management S.A. now owns 2,144,415 shares of the company’s stock valued at $61,845,000 after buying an additional 1,409,707 shares during the last quarter. Jennison Associates LLC lifted its stake in Apellis Pharmaceuticals by 51.6% in the fourth quarter. Jennison Associates LLC now owns 2,760,404 shares of the company’s stock valued at $88,084,000 after buying an additional 939,289 shares during the last quarter. JPMorgan Chase & Co. lifted its stake in Apellis Pharmaceuticals by 23.3% in the third quarter. JPMorgan Chase & Co. now owns 3,884,730 shares of the company’s stock valued at $112,036,000 after buying an additional 735,160 shares during the last quarter. Finally, Sphera Funds Management LTD. purchased a new stake in Apellis Pharmaceuticals in the third quarter valued at approximately $6,226,000. 96.29% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

APLS has been the topic of a number of research reports. The Goldman Sachs Group lowered Apellis Pharmaceuticals from a “buy” rating to a “neutral” rating and set a $36.00 price objective on the stock. in a report on Tuesday, December 17th. Bank of America decreased their price objective on Apellis Pharmaceuticals from $61.00 to $47.00 and set a “buy” rating on the stock in a report on Wednesday, November 6th. Robert W. Baird reduced their price target on Apellis Pharmaceuticals from $92.00 to $55.00 and set an “outperform” rating on the stock in a report on Thursday, November 7th. Mizuho reduced their price target on Apellis Pharmaceuticals from $39.00 to $38.00 and set a “neutral” rating on the stock in a report on Thursday, October 24th. Finally, Citigroup reduced their price target on Apellis Pharmaceuticals from $63.00 to $51.00 and set a “buy” rating on the stock in a report on Wednesday, November 6th. Eight investment analysts have rated the stock with a hold rating, ten have issued a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $46.71.

Apellis Pharmaceuticals Company Profile

Apellis Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA).